{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,22]],"date-time":"2026-09-22T22:28:54Z","timestamp":1790116134179,"version":"4.0.1"},"reference-count":37,"publisher":"Springer Science and Business Media LLC","issue":"6","license":[{"start":{"date-parts":[[2020,5,2]],"date-time":"2020-05-02T00:00:00Z","timestamp":1588377600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.springer.com\/tdm"},{"start":{"date-parts":[[2020,5,2]],"date-time":"2020-05-02T00:00:00Z","timestamp":1588377600000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/www.springer.com\/tdm"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Int Urol Nephrol"],"published-print":{"date-parts":[[2020,6]]},"DOI":"10.1007\/s11255-020-02481-3","type":"journal-article","created":{"date-parts":[[2020,5,2]],"date-time":"2020-05-02T09:03:26Z","timestamp":1588410206000},"page":"1179-1189","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":42,"title":["A unifying model of glucotoxicity in human renal proximal tubular epithelial cells and the effect of the SGLT2 inhibitor dapagliflozin"],"prefix":"10.1007","volume":"52","author":[{"ORCID":"https:\/\/orcid.org\/0000-0001-9302-1633","authenticated-orcid":false,"given":"Theodoros","family":"Eleftheriadis","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Georgios","family":"Pissas","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Konstantina","family":"Tsogka","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Evdokia","family":"Nikolaou","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Vassilios","family":"Liakopoulos","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ioannis","family":"Stefanidis","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2020,5,2]]},"reference":[{"issue":"1","key":"2481_CR1","doi-asserted-by":"publisher","first-page":"11","DOI":"10.1038\/nrneph.2016.170","volume":"13","author":"RA DeFronzo","year":"2017","unstructured":"DeFronzo RA, Norton L, Abdul-Ghani M (2017) Renal, metabolic and cardiovascular considerations of SGLT2 inhibition. Nat Rev Nephrol 13(1):11\u201326. https:\/\/doi.org\/10.1038\/nrneph.2016.170","journal-title":"Nat Rev Nephrol"},{"issue":"5","key":"2481_CR2","doi-asserted-by":"publisher","first-page":"27","DOI":"10.1007\/s11892-018-0992-6","volume":"18","author":"CCJ Dekkers","year":"2018","unstructured":"Dekkers CCJ, Gansevoort RT, Heerspink HJL (2018) New diabetes therapies and diabetic kidney disease progression: the role of SGLT-2 inhibitors. Curr Diabets Rep 18(5):27. https:\/\/doi.org\/10.1007\/s11892-018-0992-6","journal-title":"Curr Diabets Rep"},{"issue":"4","key":"2481_CR3","doi-asserted-by":"publisher","first-page":"303","DOI":"10.1161\/CIRCULATIONAHA.118.037418","volume":"140","author":"K Kidokoro","year":"2019","unstructured":"Kidokoro K, Cherney DZI, Bozovic A, Nagasu H, Satoh M, Kanda E, Sasaki T, Kashihara N (2019) Evaluation of glomerular hemodynamic function by empagliflozin in diabetic mice using in vivo imaging. Circulation 140(4):303\u2013315. https:\/\/doi.org\/10.1161\/CIRCULATIONAHA.118.037418","journal-title":"Circulation"},{"issue":"2","key":"2481_CR4","doi-asserted-by":"publisher","first-page":"489","DOI":"10.1016\/j.kint.2019.02.033","volume":"96","author":"GJ Mayer","year":"2019","unstructured":"Mayer GJ, Wanner C, Weir MR, Inzucchi SE, Koitka-Weber A, Hantel S, von Eynatten M, Zinman B, Cherney DZI (2019) Analysis from the EMPA-REG OUTCOME((R)) trial indicates empagliflozin may assist in preventing the progression of chronic kidney disease in patients with type 2 diabetes irrespective of medications that alter intrarenal hemodynamics. Kidney Int 96(2):489\u2013504. https:\/\/doi.org\/10.1016\/j.kint.2019.02.033","journal-title":"Kidney Int"},{"issue":"5","key":"2481_CR5","doi-asserted-by":"publisher","first-page":"406","DOI":"10.1002\/dmrr.2407","volume":"29","author":"S Maeda","year":"2013","unstructured":"Maeda S, Matsui T, Takeuchi M, Yamagishi S-I (2013) Sodium-glucose cotransporter 2-mediated oxidative stress augments advanced glycation end products-induced tubular cell apoptosis. Diabetes\/Metab Res Rev 29(5):406\u2013412. https:\/\/doi.org\/10.1002\/dmrr.2407","journal-title":"Diabetes\/Metab Res Rev"},{"issue":"2","key":"2481_CR6","doi-asserted-by":"publisher","first-page":"e54442","DOI":"10.1371\/journal.pone.0054442","volume":"8","author":"U Panchapakesan","year":"2013","unstructured":"Panchapakesan U, Pegg K, Gross S, Komala MG, Mudaliar H, Forbes J, Pollock C, Mather A (2013) Effects of SGLT2 inhibition in human kidney proximal tubular cells-renoprotection in diabetic nephropathy? PLoS ONE 8(2):e54442. https:\/\/doi.org\/10.1371\/journal.pone.0054442","journal-title":"PLoS ONE"},{"issue":"09","key":"2481_CR7","doi-asserted-by":"publisher","first-page":"686","DOI":"10.1055\/s-0034-1395609","volume":"47","author":"A Ojima","year":"2015","unstructured":"Ojima A, Matsui T, Nishino Y, Nakamura N, Yamagishi S (2015) Empagliflozin, an inhibitor of sodium-glucose cotransporter 2 exerts anti-inflammatory and antifibrotic effects on experimental diabetic nephropathy partly by suppressing AGEs-receptor axis. Horm Metab Res 47(09):686\u2013692. https:\/\/doi.org\/10.1055\/s-0034-1395609","journal-title":"Horm Metab Res"},{"issue":"03","key":"2481_CR8","doi-asserted-by":"publisher","first-page":"191","DOI":"10.1055\/s-0035-1555791","volume":"48","author":"Y Ishibashi","year":"2015","unstructured":"Ishibashi Y, Matsui T, Yamagishi S (2015) Tofogliflozin, a highly selective inhibitor of SGLT2 blocks proinflammatory and proapoptotic effects of glucose overload on proximal tubular cells partly by suppressing oxidative stress generation. Horm Metab Res 48(03):191\u2013195. https:\/\/doi.org\/10.1055\/s-0035-1555791","journal-title":"Horm Metab Res"},{"issue":"4","key":"2481_CR9","doi-asserted-by":"publisher","first-page":"e00239","DOI":"10.1002\/prp2.239","volume":"4","author":"T Hatanaka","year":"2016","unstructured":"Hatanaka T, Ogawa D, Tachibana H, Eguchi J, Inoue T, Yamada H, Takei K, Makino H, Wada J (2016) Inhibition of SGLT2 alleviates diabetic nephropathy by suppressing high glucose-induced oxidative stress in type 1 diabetic mice. Pharmacol Res Perspect 4(4):e00239. https:\/\/doi.org\/10.1002\/prp2.239","journal-title":"Pharmacol Res Perspect"},{"key":"2481_CR10","doi-asserted-by":"publisher","DOI":"10.3389\/fendo.2019.00441","author":"F Huang","year":"2019","unstructured":"Huang F, Zhao Y, Wang Q, Hillebrands J-L, Jvd B, Ji L, An T, Qin G (2019) Dapagliflozin attenuates renal tubulointerstitial fibrosis associated with type 1 diabetes by regulating STAT1\/TGF\u03b21 signaling. Front Endocrinol. https:\/\/doi.org\/10.3389\/fendo.2019.00441","journal-title":"Front Endocrinol"},{"issue":"6","key":"2481_CR11","doi-asserted-by":"publisher","first-page":"1615","DOI":"10.2337\/diabetes.54.6.1615","volume":"54","author":"M Brownlee","year":"2005","unstructured":"Brownlee M (2005) The pathobiology of diabetic complications: a unifying mechanism. Diabetes 54(6):1615\u20131625. https:\/\/doi.org\/10.2337\/diabetes.54.6.1615","journal-title":"Diabetes"},{"issue":"9","key":"2481_CR12","doi-asserted-by":"publisher","first-page":"1058","DOI":"10.1161\/circresaha.110.223545","volume":"107","author":"F Giacco","year":"2010","unstructured":"Giacco F, Brownlee M, Schmidt AM (2010) Oxidative stress and diabetic complications. Circ Res 107(9):1058\u20131070. https:\/\/doi.org\/10.1161\/circresaha.110.223545","journal-title":"Circ Res"},{"issue":"10","key":"2481_CR13","doi-asserted-by":"publisher","first-page":"1731","DOI":"10.1007\/s11255-016-1377-x","volume":"48","author":"T Eleftheriadis","year":"2016","unstructured":"Eleftheriadis T, Tsogka K, Pissas G, Antoniadi G, Liakopoulos V, Stefanidis I (2016) Activation of general control nonderepressible 2 kinase protects human glomerular endothelial cells from harmful high-glucose-induced molecular pathways. Int Urol Nephrol 48(10):1731\u20131739. https:\/\/doi.org\/10.1007\/s11255-016-1377-x","journal-title":"Int Urol Nephrol"},{"issue":"7","key":"2481_CR14","doi-asserted-by":"publisher","first-page":"1049","DOI":"10.1172\/jci18127","volume":"112","author":"X Du","year":"2003","unstructured":"Du X, Matsumura T, Edelstein D, Rossetti L, Zsengell\u00e9r Z, Szab\u00f3 C, Brownlee M (2003) Inhibition of GAPDH activity by poly(ADP-ribose) polymerase activates three major pathways of hyperglycemic damage in endothelial cells. J Clin Investig 112(7):1049\u20131057. https:\/\/doi.org\/10.1172\/jci18127","journal-title":"J Clin Investig"},{"issue":"6779","key":"2481_CR15","doi-asserted-by":"publisher","first-page":"787","DOI":"10.1038\/35008121","volume":"404","author":"T Nishikawa","year":"2000","unstructured":"Nishikawa T, Edelstein D, Du XL, Yamagishi S-i, Matsumura T, Kaneda Y, Yorek MA, Beebe D, Oates PJ, Hammes H-P, Giardino I, Brownlee M (2000) Normalizing mitochondrial superoxide production blocks three pathways of hyperglycaemic damage. Nature 404(6779):787\u2013790. https:\/\/doi.org\/10.1038\/35008121","journal-title":"Nature"},{"issue":"Pt 20","key":"2481_CR16","doi-asserted-by":"publisher","first-page":"4589","DOI":"10.1242\/jcs.02579","volume":"118","author":"PN Moynagh","year":"2005","unstructured":"Moynagh PN (2005) The NF-kappaB pathway. J Cell Sci 118(Pt 20):4589\u20134592. https:\/\/doi.org\/10.1242\/jcs.02579","journal-title":"J Cell Sci"},{"issue":"1","key":"2481_CR17","doi-asserted-by":"publisher","first-page":"115","DOI":"10.1172\/jci119503","volume":"100","author":"D Koya","year":"1997","unstructured":"Koya D, Jirousek MR, Lin YW, Ishii H, Kuboki K, King GL (1997) Characterization of protein kinase C beta isoform activation on the gene expression of transforming growth factor-beta, extracellular matrix components, and prostanoids in the glomeruli of diabetic rats. J Clin Investig 100(1):115\u2013126. https:\/\/doi.org\/10.1172\/jci119503","journal-title":"J Clin Investig"},{"key":"2481_CR18","doi-asserted-by":"publisher","DOI":"10.3389\/fphar.2017.00798","author":"SV Suryavanshi","year":"2017","unstructured":"Suryavanshi SV, Kulkarni YA (2017) NF-\u03ba\u03b2: a potential target in the management of vascular complications of diabetes. Front Pharmacol. https:\/\/doi.org\/10.3389\/fphar.2017.00798","journal-title":"Front Pharmacol"},{"issue":"1","key":"2481_CR19","doi-asserted-by":"publisher","first-page":"154","DOI":"10.1016\/s0014-5793(03)00641-0","volume":"546","author":"L Wells","year":"2003","unstructured":"Wells L, Hart GW (2003) O-GlcNAc turns twenty: functional implications for post-translational modification of nuclear and cytosolic proteins with a sugar. FEBS Lett 546(1):154\u2013158. https:\/\/doi.org\/10.1016\/s0014-5793(03)00641-0","journal-title":"FEBS Lett"},{"issue":"1","key":"2481_CR20","doi-asserted-by":"publisher","first-page":"160","DOI":"10.1172\/jci119875","volume":"101","author":"V Kolm-Litty","year":"1998","unstructured":"Kolm-Litty V, Sauer U, Nerlich A, Lehmann R, Schleicher ED (1998) High glucose-induced transforming growth factor beta1 production is mediated by the hexosamine pathway in porcine glomerular mesangial cells. J Clin Investig 101(1):160\u2013169. https:\/\/doi.org\/10.1172\/jci119875","journal-title":"J Clin Investig"},{"issue":"22","key":"2481_CR21","doi-asserted-by":"publisher","first-page":"12222","DOI":"10.1073\/pnas.97.22.12222","volume":"97","author":"XL Du","year":"2000","unstructured":"Du XL, Edelstein D, Rossetti L, Fantus IG, Goldberg H, Ziyadeh F, Wu J, Brownlee M (2000) Hyperglycemia-induced mitochondrial superoxide overproduction activates the hexosamine pathway and induces plasminogen activator inhibitor-1 expression by increasing Sp1 glycosylation. Proc Natl Acad Sci 97(22):12222\u201312226. https:\/\/doi.org\/10.1073\/pnas.97.22.12222","journal-title":"Proc Natl Acad Sci"},{"issue":"1","key":"2481_CR22","doi-asserted-by":"publisher","first-page":"291","DOI":"10.2337\/db13-0316","volume":"63","author":"F Giacco","year":"2013","unstructured":"Giacco F, Du X, D'Agati VD, Milne R, Sui G, Geoffrion M, Brownlee M (2013) Knockdown of glyoxalase 1 mimics diabetic nephropathy in nondiabetic mice. Diabetes 63(1):291\u2013299. https:\/\/doi.org\/10.2337\/db13-0316","journal-title":"Diabetes"},{"key":"2481_CR23","doi-asserted-by":"publisher","first-page":"158","DOI":"10.1016\/j.ejphar.2018.06.001","volume":"833","author":"D Sanajou","year":"2018","unstructured":"Sanajou D, Ghorbani Haghjo A, Argani H, Aslani S (2018) AGE-RAGE axis blockade in diabetic nephropathy: Current status and future directions. Eur J Pharmacol 833:158\u2013164. https:\/\/doi.org\/10.1016\/j.ejphar.2018.06.001","journal-title":"Eur J Pharmacol"},{"issue":"11","key":"2481_CR24","doi-asserted-by":"publisher","first-page":"2921","DOI":"10.2337\/diabetes.53.11.2921","volume":"53","author":"V Thallas-Bonke","year":"2004","unstructured":"Thallas-Bonke V, Lindschau C, Rizkalla B, Bach LA, Boner G, Meier M, Haller H, Cooper ME, Forbes JM (2004) Attenuation of extracellular matrix accumulation in diabetic nephropathy by the advanced glycation end product cross-link breaker ALT-711 via a protein kinase C-alpha-dependent pathway. Diabetes 53(11):2921\u20132930. https:\/\/doi.org\/10.2337\/diabetes.53.11.2921","journal-title":"Diabetes"},{"issue":"1","key":"2481_CR25","doi-asserted-by":"publisher","first-page":"17","DOI":"10.1007\/s40262-013-0104-3","volume":"53","author":"S Kasichayanula","year":"2013","unstructured":"Kasichayanula S, Liu X, LaCreta F, Griffen SC, Boulton DW (2013) Clinical pharmacokinetics and pharmacodynamics of dapagliflozin, a selective inhibitor of sodium-glucose co-transporter type 2. Clin Pharmacokinet 53(1):17\u201327. https:\/\/doi.org\/10.1007\/s40262-013-0104-3","journal-title":"Clin Pharmacokinet"},{"issue":"1","key":"2481_CR26","doi-asserted-by":"publisher","first-page":"94","DOI":"10.1124\/jpet.116.232025","volume":"358","author":"R Ohgaki","year":"2016","unstructured":"Ohgaki R, Wei L, Yamada K, Hara T, Kuriyama C, Okuda S, Ueta K, Shiotani M, Nagamori S, Kanai Y (2016) Interaction of the sodium\/glucose cotransporter (SGLT) 2 inhibitor canagliflozin with SGLT1 and SGLT2. J Pharmacol Exp Ther 358(1):94\u2013102. https:\/\/doi.org\/10.1124\/jpet.116.232025","journal-title":"J Pharmacol Exp Ther"},{"issue":"6","key":"2481_CR27","doi-asserted-by":"publisher","first-page":"479","DOI":"10.1111\/j.1365-2796.2005.01570.x","volume":"258","author":"B Fadeel","year":"2005","unstructured":"Fadeel B, Orrenius S (2005) Apoptosis: a basic biological phenomenon with wide-ranging implications in human disease. J Intern Med 258(6):479\u2013517. https:\/\/doi.org\/10.1111\/j.1365-2796.2005.01570.x","journal-title":"J Intern Med"},{"issue":"4","key":"2481_CR28","doi-asserted-by":"publisher","first-page":"592","DOI":"10.3109\/0886022x.2013.773836","volume":"35","author":"T Eleftheriadis","year":"2013","unstructured":"Eleftheriadis T, Antoniadi G, Pissas G, Liakopoulos V, Stefanidis I (2013) The renal endothelium in diabetic nephropathy. Ren Fail 35(4):592\u2013599. https:\/\/doi.org\/10.3109\/0886022x.2013.773836","journal-title":"Ren Fail"},{"issue":"1","key":"2481_CR29","doi-asserted-by":"publisher","first-page":"395","DOI":"10.1146\/annurev.pathol.4.110807.092150","volume":"6","author":"YS Kanwar","year":"2011","unstructured":"Kanwar YS, Sun L, Xie P, Liu F-Y, Chen S (2011) A glimpse of various pathogenetic mechanisms of diabetic nephropathy. Annu Rev Pathol 6(1):395\u2013423. https:\/\/doi.org\/10.1146\/annurev.pathol.4.110807.092150","journal-title":"Annu Rev Pathol"},{"issue":"5","key":"2481_CR30","doi-asserted-by":"publisher","first-page":"469","DOI":"10.1159\/000320749","volume":"32","author":"KJ Kelly","year":"2010","unstructured":"Kelly KJ, Dominguez JH (2010) Rapid progression of diabetic nephropathy is linked to inflammation and episodes of acute renal failure. Am J Nephrol 32(5):469\u2013475. https:\/\/doi.org\/10.1159\/000320749","journal-title":"Am J Nephrol"},{"key":"2481_CR31","doi-asserted-by":"publisher","DOI":"10.3389\/fendo.2018.00225","author":"L Winter","year":"2018","unstructured":"Winter L, Wong LA, Jerums G, Seah J-M, Clarke M, Tan SM, Coughlan MT, MacIsaac RJ, Ekinci EI (2018) Use of readily accessible inflammatory markers to predict diabetic kidney disease. Front Endocrinol. https:\/\/doi.org\/10.3389\/fendo.2018.00225","journal-title":"Front Endocrinol"},{"issue":"8","key":"2481_CR32","doi-asserted-by":"publisher","first-page":"787","DOI":"10.1093\/molehr\/7.8.787","volume":"7","author":"CL Elliott","year":"2001","unstructured":"Elliott CL, Allport VC, Loudon JA, Wu GD, Bennett PR (2001) Nuclear factor-kappa B is essential for up-regulation of interleukin-8 expression in human amnion and cervical epithelial cells. Mol Hum Reprod 7(8):787\u2013790. https:\/\/doi.org\/10.1093\/molehr\/7.8.787","journal-title":"Mol Hum Reprod"},{"key":"2481_CR33","first-page":"236","volume":"51","author":"K Matsushima","year":"1992","unstructured":"Matsushima K, Baldwin ET, Mukaida N (1992) Interleukin-8 and MCAF: novel leukocyte recruitment and activating cytokines. Chem Immunol 51:236\u2013265","journal-title":"Chem Immunol"},{"issue":"3","key":"2481_CR34","doi-asserted-by":"publisher","first-page":"F412","DOI":"10.1152\/ajprenal.00445.2017","volume":"314","author":"H Rajasekeran","year":"2018","unstructured":"Rajasekeran H, Reich HN, Hladunewich MA, Cattran D, Lovshin JA, Lytvyn Y, Bjornstad P, Lai V, Tse J, Cham L, Majumder S, Bowskill BB, Kabir MG, Advani SL, Gibson IW, Sood MM, Advani A, Cherney DZI (2018) Dapagliflozin in focal segmental glomerulosclerosis: a combined human-rodent pilot study. Am J Physiol Renal Physiol 314(3):F412\u2013F422. https:\/\/doi.org\/10.1152\/ajprenal.00445.2017","journal-title":"Am J Physiol Renal Physiol"},{"issue":"8","key":"2481_CR35","doi-asserted-by":"publisher","first-page":"606","DOI":"10.1016\/s2213-8587(19)30180-9","volume":"7","author":"O Mosenzon","year":"2019","unstructured":"Mosenzon O, Wiviott SD, Cahn A, Rozenberg A, Yanuv I, Goodrich EL, Murphy SA, Heerspink HJL, Zelniker TA, Dwyer JP, Bhatt DL, Leiter LA, McGuire DK, Wilding JPH, Kato ET, Gause-Nilsson IAM, Fredriksson M, Johansson PA, Langkilde AM, Sabatine MS, Raz I (2019) Effects of dapagliflozin on development and progression of kidney disease in patients with type 2 diabetes: an analysis from the DECLARE\u2013TIMI 58 randomised trial. Lancet Diabetes Endocrinol 7(8):606\u2013617. https:\/\/doi.org\/10.1016\/s2213-8587(19)30180-9","journal-title":"Lancet Diabetes Endocrinol"},{"issue":"24","key":"2481_CR36","doi-asserted-by":"publisher","first-page":"2295","DOI":"10.1056\/NEJMoa1811744","volume":"380","author":"V Perkovic","year":"2019","unstructured":"Perkovic V, Jardine MJ, Neal B, Bompoint S, Heerspink HJL, Charytan DM, Edwards R, Agarwal R, Bakris G, Bull S, Cannon CP, Capuano G, Chu P-L, de Zeeuw D, Greene T, Levin A, Pollock C, Wheeler DC, Yavin Y, Zhang H, Zinman B, Meininger G, Brenner BM, Mahaffey KW (2019) Canagliflozin and renal outcomes in type 2 diabetes and nephropathy. N Engl J Med 380(24):2295\u20132306. https:\/\/doi.org\/10.1056\/NEJMoa1811744","journal-title":"N Engl J Med"},{"issue":"8","key":"2481_CR37","doi-asserted-by":"publisher","first-page":"1142","DOI":"10.2215\/cjn.00060119","volume":"14","author":"SL Tummalapalli","year":"2019","unstructured":"Tummalapalli SL, Powe NR, Keyhani S (2019) Trends in quality of care for patients with CKD in the United States. Clin J Am Soc Nephrol 14(8):1142\u20131150. https:\/\/doi.org\/10.2215\/cjn.00060119","journal-title":"Clin J Am Soc Nephrol"}],"container-title":["International Urology and Nephrology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s11255-020-02481-3.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s11255-020-02481-3\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s11255-020-02481-3.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2021,5,3]],"date-time":"2021-05-03T12:49:42Z","timestamp":1620046182000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s11255-020-02481-3"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2020,5,2]]},"references-count":37,"journal-issue":{"issue":"6","published-print":{"date-parts":[[2020,6]]}},"alternative-id":["2481"],"URL":"https:\/\/doi.org\/10.1007\/s11255-020-02481-3","relation":{},"ISSN":["0301-1623","1573-2584"],"issn-type":[{"value":"0301-1623","type":"print"},{"value":"1573-2584","type":"electronic"}],"subject":[],"published":{"date-parts":[[2020,5,2]]},"assertion":[{"value":"17 August 2019","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"21 April 2020","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"2 May 2020","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Compliance with ethical standards"}},{"value":"The authors report no conflicts of interest.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Conflict of interest"}},{"value":"This article does not contain any studies with human participants or animals performed by any of the authors.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Research involving human participants and\/or animals"}},{"value":"Not applicable, the study does not involve human participants.","order":4,"name":"Ethics","group":{"name":"EthicsHeading","label":"Informed consent"}}]}}